Although generally regarded as a pro-inflammatory cytokine, IL-6 also has anti-inflammatory effects and can induce an anti-inflammatory environment.[28,29] Recently, Cortellini et al[30] reported the predictive value of SM mass in NSCLC patients treated with second-line nivolumab. The gene discussed is IL6; the disease is non-small cell lung carcinoma.